Diabetes mellitus continues to evolve as a global public health problem. Early identification of renal functions is important for diabetic patients. Serum Cystatin C may be one of the sensitive indicators of GFR. We in the present study tried to evaluate the usefulness and sensitivity of Cystatin C and creatinine in patients with diabetes mellitus type 2 in comparison with controls. A total of n=88 patients divided into two groups Group I (DM type II) n=44 and Group II (normal controls) n=44 were included in the study. The group I patients was subdivided into three subgroups based on the albuminuria. The subgroup [A] were the patients with microalbuminruia n=13, Subgroup [B] were patients with macroalbuminruia n= 17, Subgroup [C] were patients with normoalbuminuria n=14. Results: In group I the mean age was 57.5 ± 3.5 years and the Mean age in the control group II was 55.5 ± 2.5 years. Cystatin C was more sensitive then creatinine in microalbumin subgroup [A] urea (73.3 and 75.1 % respectively) in Subgroup [B] the values were [63.5 and 69.8 % respectively] in normoalbuminuria subgroup [C] 59.5 and 54.6 % respectively While in control group serum creatinine was slightly more sensitive than the Cystatin C 42.3 and 41.5 % respectively. Conclusion: it can be concluded that serum Cystatin C is a good marker of renal nephropathy and impaired renal functions in diabetic patients. In the study patients with macroalbuminuria had highest sensitivity with Cystatin C as compared to creatinine. It may be considered as an alternative marker of nephropathy instead of albuminuria in patients with decreased GFR and renal functions.
Introduction
Diabetes mellitus is a global health problem it is the combined result of an increase in life expectancy with a concomitant increase in access to refined carbohydrates and decrease in physical activity. Diabetes has reached epidemic proportions with current estimates of prevalence to about 170 million [1] . Chronic diabetes is associated with damage to several organs and dysfunctions especially with eyes, nerves, heart, kidneys and blood vessels [2] . The macrovascular complications include cardiomyopathy, http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i9.103 vasculopathy, dermatopathy and atherosclerosis [3] . Diabetic nephropathy is the leading cause of kidney replacement therapy and affects 40% of both type I and type II diabetic patients [4] . Diabetic nephropathy is defined by the presence of proteinuria in the absence of other renal diseases. It is more likely to occur in patients with poor glycemic control, hypertension, glomerular hyperfiltration and to an extent genetic predisposition. The early features of diabetic renal changes are microalbuminuria 30 -300mg/day, glomerular hyperfiltration and renal hypertrophy with increased basement membrane thickness and mesangial expansion and accumulation of extracellular protein like collagen fibronectin and laminin [5] . Microalbuminruia precedes the development of macroalbuminruia and is predictive of future nephropathy. The onset of microalbuminuria in the absence of effective therapy usually leads to a gradual decline of GFR [6] . The Kidney Disease Improving Global Outcome KDIGO guidelines were the first to incorporate Cystatin C based formulas in addition to creatinine and GFR estimating formulae. Since creatinine is less accurate and can be affected by several factors including drugs [7] . Cystatin C is considered a good marker of kidney functions because it is solely filtered by the glomerulus and is not handled by renal tubules and is generated as a constant rate by cells of the body. Some studies have suggested that Cystatin C may detect a mild to moderate decrease in GFR which may not be evident with serum creatinine-based measurements. With this background, we in the present study tried to evaluate the sensitivity of Cystatin C as a marker of nephropathy in diabetic patients.
Material and Methods
The present study was conducted in the Departments of General Medicine and Biochemistry, ESIC Medical College and Hospital, Hyderabad from April 2016 to May 2018. Institutional Ethical committee permission was obtained for the study. Written consent was obtained for the study. The patients were grouped into two groups; Group I and Group II initially n=50 patients were included into both groups however 6 patients of the group I did not turned for follow up hence a total of n=44 patients were included similarly the group II patients were also reduced to n=44. The Group I was the known diabetic (Type II) patients who on treatment and group II patients were carefully selected normal patients without diabetes mellitus to act as age and sex-matched controls. Excluded patients were with other illnesses like malignancy, history of cardiovascular or renal diseases, history of hypertension, rheumatoid arthritis, and bronchial asthma. The group I patients was subdivided into three subgroups based on the albuminuria. The subgroup [A] were the patients with microalbuminruia (albumin excretion between 30 mg/day and 300 mg/day), subgroup [B] were patients with macroalbuminruia albumin excretion >300 mg/day subgroup [C] were patients with normoalbuminuria (albumin excretion in urine persistently lower than 30 mg/day). The anthropometric measurements and blood pressure were recorded. Blood samples were collected to determine FBS, HbA1c, serum uric acid, blood urea, serum creatinine. HbA1c was measured by chromatography based HPLC assay and expressed as a percentage. Serum creatinine was measured by Jaffe's method and serum Cystatin C was measured by ELISA. Microalbuminuria was determined by immunoturbidimetric method from urine collected over 24 hours expressed as mg/day. The results were recorded in MS Excel spreadsheet and analyzed by SPSS version 19 on windows format. A p-value of < 0.05 was considered as significant.
Results
The patients were grouped based on the age the range of the patients was from 40 to 65 years. In group I the mean age was 57.5 ± 3.5 years and the Mean age in the control group II was 55.5 ± 2.5 years. The majority of patients in the group I and group II belonged to age groups 56 to 65 years.
The distribution of patients in both groups is given in table 1. 
Discussion
Diabetes is marked by sustained hyperglycemia which results in changes in metabolic and hemodynamic functions [8] . Renal involvement is an important feature resulting in a decrease in renal functions over a period of time [9] . Diabetic nephropathy is an important cause of morbidity and mortality in type I and types II diabetes mellitus [10] . Hence, specific tests are necessary to monitor early signs of diabetic nephropathy to prevent the development of the end-stage renal disease. Earlier microalbuminuria with a decrease in creatinine clearance and an increase in serum creatinine was tested for diabetic nephropathy [11] . However, it has been shown that a decline in renal functions in patients with diabetes is not always accompanied by an increase of ACR [12] . Biomarkers for accurate estimation of renal function were searched for and one they were Cystatin C. Cystatin C is small protein MW 13kDa is a member of cysteine proteinase inhibitor family. It is produced constantly by all the nucleated cells of the body. Due to its small size, it is freely filtered by the glomerulus and is not secreted but is fully reabsorbed and broken down by the renal tubules. Cystatin C concentration was found to an endogenous marker of GFR and was considered superior to creatinine [11] . In the present study out of n=44 patients, n=30 (68.18%) were with diabetic nephropathy showing microalbuminuria and macroalbuminuria. The serum creatinine and Cystatin C was found to be highest in patients with macroalbuminuria, as it is known that macroalbuminuria is the advanced stage of nephropathy. It was found in the study that patients with macroalbuminuria had diabetes with duration > 10 years which indicates progressive renal damage with chronic diabetes mellitus. In this study the sensitivity of serum Cystatin C was highest in the macroalbuminuria group at 75.1% followed by microalbuminuria group at 73.3% the similar values of the sensitivity of serum creatinine in macroalbuminuria group was 69.8% and microalbumin group was 63.5% and the p values were found to be highly significant in cystatin group. In a similar study by H J Waheed [5] in Iraqi patients found the serum Cystatin C in microalbuminuria group to be 76.2% and macroalbuminuria group to be 68.95% and the sensitivity of serum creatinine in microalbuminuria group 72.08% and macroalbuminuria group 61.33% agreeing with the results of the present study. The interesting finding of our study was that Cystatin C had a lower sensitivity to the normoalbuminuria group and the control patients. It must be then appropriate to consider that elevated Cystatin C levels when associated with microalbuminuria or macroalbuminuria is of clinical significance in diabetic patients. Studies have shown that Cystatin C now can be widely used and can replace creatinine for assessment of GFR in clinical practice. Roos et al; have concluded that Cystatin C is superior to serum creatinine as the marker of kidney function [13] .
Conclusion
Within the limitations of the present study, it can be concluded that serum Cystatin C is a good marker of renal nephropathy and impaired renal functions in diabetic patients. In this study patients with macroalbuminuria had highest sensitivity with Cystatin C as compared to creatinine. It may be considered as an alternative marker of nephropathy instead of albuminuria in patients with decreased GFR and renal functions.
